$CARM
Carisma Therapeutics Inc Stock $carm

$carm Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000148500323000116 Filed on August 10, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$3.800M	$3.600M	$0.00
YoY Change	-90.5%		-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.620M	$6.010M	$15.59M
YoY Change	-18.68%	-61.45%	129.08%
% of Gross Profit
Research & Development	$19.55M	$18.52M	$29.94M
YoY Change	567.04%	-38.16%	314.28%
% of Gross Profit
Depreciation & Amortization	$700.0K	$710.0K	$3.000K
YoY Change		23566.67%	-91.18%
% of Gross Profit
Operating Expenses	$26.17M	$24.53M	$36.00M
YoY Change	29.44%	-31.87%	30.27%
Operating Profit	-$22.34M	-$20.97M	-$36.00M
YoY Change	-212.96%	-41.76%	41.73%
Interest Expense	$941.0K	$1.177M	-$771.0K
YoY Change	-203.63%	-252.66%
% of Operating Profit
Other Income/Expense, Net			$162.0K
YoY Change			-476.74%
Pretax Income	-$21.40M	-$19.79M	-$35.84M
YoY Change	-204.61%	-44.77%	40.85%
Income Tax	$0.00	$88.00K	-$3.875M
% Of Pretax Income
Net Earnings	-$21.40M	-$19.88M	-$31.96M
YoY Change	-204.62%	-37.81%	25.62%
Net Earnings / Revenue	-563.24%	-552.11%
Basic Earnings Per Share	-$0.53	-$0.49	-$0.16
Diluted Earnings Per Share	-$0.53	-$0.49	-$0.16
COMMON SHARES
Basic Shares Outstanding	40.28M shares	40.25M	199.5M shares
Diluted Shares Outstanding	40.29M shares	40.26M shares	199.5M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$94.10M	$117.1M	$141.5M
YoY Change	-47.0%	-17.27%	-6.28%
Cash & Equivalents	$83.13M	$76.35M	$72.09M
Short-Term Investments	$11.00M	$40.70M	$69.45M
Other Short-Term Assets	$3.400M	$5.100M	$757.0K
YoY Change	545.16%	573.71%	-96.52%
Inventory
Prepaid Expenses
Receivables			$73.00K
Other Receivables			$14.00M
Total Short-Term Assets	$97.57M	$122.2M	$156.4M
YoY Change	-49.28%	-21.88%	-10.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.379M	$7.590M	$30.00K
YoY Change		25200.0%	-72.48%
Goodwill			$0.00
YoY Change			-100.0%
Intangibles			$0.00
YoY Change			-100.0%
Long-Term Investments			$19.64M
YoY Change
Other Assets	$200.0K	$200.0K	$42.00K
YoY Change		376.19%	-79.51%
Total Long-Term Assets	$9.219M	$10.81M	$19.74M
YoY Change	25.16%	-45.23%	-70.06%
TOTAL ASSETS
Total Short-Term Assets	$97.57M	$122.2M	$156.4M
Total Long-Term Assets	$9.219M	$10.81M	$19.74M
Total Assets	$106.8M	$133.0M	$176.2M
YoY Change	-46.53%	-24.49%	-26.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.409M	$2.487M	$1.667M
YoY Change	368.68%	49.19%	35.75%
Accrued Expenses	$7.026M	$9.614M	$29.85M
YoY Change	-79.21%	-67.79%	463.12%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$500.0K	$1.200M
YoY Change
Total Short-Term Liabilities	$12.95M	$17.97M	$32.01M
YoY Change	-62.67%	-43.84%	70.0%
LONG-TERM LIABILITIES
Long-Term Debt	$500.0K	$600.0K	$0.00
YoY Change
Other Long-Term Liabilities	$1.176M	$1.809M	$1.800M
YoY Change		0.5%	4086.05%
Total Long-Term Liabilities	$1.176M	$1.809M	$1.800M
YoY Change		0.5%	-98.96%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.95M	$17.97M	$32.01M
Total Long-Term Liabilities	$1.176M	$1.809M	$1.800M
Total Liabilities	$60.49M	$66.31M	$33.81M
YoY Change	74.34%	96.15%	-82.37%
SHAREHOLDERS EQUITY
Retained Earnings	-$224.1M	-$202.7M	-$349.0M
YoY Change	-31.79%	-41.92%	-12.06%
Common Stock	$40.00K	$40.00K	$199.0K
YoY Change	-80.2%	-79.9%	5.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$46.30M	$66.71M	$142.4M
YoY Change
Total Liabilities & Shareholders Equity	$106.8M	$133.0M	$176.2M
YoY Change	-46.53%	-24.49%	-26.92%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$21.40M	-$19.88M	-$31.96M
YoY Change	-204.62%	-37.81%	25.62%
Depreciation, Depletion And Amortization	$700.0K	$710.0K	$3.000K
YoY Change		23566.67%	-91.18%
Cash From Operating Activities	-$21.00M	-$18.55M	-$8.595M
YoY Change	-188.78%	115.82%	-62.85%
INVESTING ACTIVITIES
Capital Expenditures	$190.0K	$240.0K	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$30.00M	$36.00M	-$89.10M
YoY Change	-221.76%	-140.41%
Cash From Investing Activities	$29.81M	$35.76M	-$89.10M
YoY Change	-220.99%	-140.14%	181726.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-2.030M	-3.630M	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-21.00M	-18.55M	-8.595M
Cash From Investing Activities	29.81M	35.76M	-89.10M
Cash From Financing Activities	-2.030M	-3.630M	0.000
Net Change In Cash	6.780M	13.58M	-97.69M
YoY Change	-789.73%	-113.9%	-337.82%
FREE CASH FLOW
Cash From Operating Activities	-$21.00M	-$18.55M	-$8.595M
Capital Expenditures	$190.0K	$240.0K	$0.00
Free Cash Flow	-$21.19M	-$18.79M	-$8.595M
YoY Change		118.62%	-62.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40269576	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40269576	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2217737	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2217737	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.49
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.20
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.20
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-12.69
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-12.69
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2061643	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2061643	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2060819	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2060819	shares
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	8700885	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	107808000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-81784000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	89000	usd
CY2022Q1	carm	Other Comprehensive Income Loss Marketable Securities Gain Loss After Adjustment And Tax OtherComprehensiveIncomeLossMarketableSecuritiesGainLossAfterAdjustmentAndTax	-158000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-11312000	usd
CY2022Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	8700885	shares
CY2022Q1	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	107808000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-93165000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	58000	usd
CY2022Q2	carm	Other Comprehensive Income Loss Marketable Securities Gain Loss After Adjustment And Tax OtherComprehensiveIncomeLossMarketableSecuritiesGainLossAfterAdjustmentAndTax	-39000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-14848000	usd
CY2022Q2	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	8700885	shares
CY2022Q2	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	107808000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-107994000	usd
	us-gaap	Profit Loss ProfitLoss	-44518000	usd
	us-gaap	Profit Loss ProfitLoss	-26160000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1420000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	463000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	595000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	147000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2683000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1620000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1283000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1305000	usd
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-84000	usd
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-701000	usd
	carm	Accretion On Marketable Securities AccretionOnMarketableSecurities	569000	usd
	carm	Accretion On Marketable Securities AccretionOnMarketableSecurities	0	usd
	carm	Noncash Interest Expense NoncashInterestExpense	68000	usd
	carm	Noncash Interest Expense NoncashInterestExpense	4000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1210000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1324000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	659000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	674000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1618000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-484000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1043000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	45447000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1915000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2088000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-44081000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	20305000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	34460000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	42103000	usd
	carm	Payments For Proceeds From Marketable Securities PaymentsForProceedsFromMarketableSecurities	-67000000	usd
	carm	Payments For Proceeds From Marketable Securities PaymentsForProceedsFromMarketableSecurities	0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	382000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2038000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	32158000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-44141000	usd
	carm	Cash Cash Equivalents And Restricted Cash Acquired In Reverse Recapitalization Financing Activities CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities	37903000	usd
	carm	Cash Cash Equivalents And Restricted Cash Acquired In Reverse Recapitalization Financing Activities CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities	0	usd
	carm	Payment Of Finance Costs Reverse Recapitalization Financing Activities PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities	5202000	usd
	carm	Payment Of Finance Costs Reverse Recapitalization Financing Activities PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	30640000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	213000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	17000	usd
	carm	Proceeds From Failed Sale Leaseback Transaction ProceedsFromFailedSaleLeasebackTransaction	1020000	usd
	carm	Proceeds From Failed Sale Leaseback Transaction ProceedsFromFailedSaleLeasebackTransaction	0	usd
	carm	Payment Of Finance Liability Failed Sale Leaseback Transaction PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction	88000	usd
	carm	Payment Of Finance Liability Failed Sale Leaseback Transaction PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction	0	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	35000000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	52000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	64112000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	34983000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	52189000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	11147000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24194000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28551000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	76383000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39698000	usd
	us-gaap	Interest Paid Net InterestPaidNet	88000	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	carm	Noncash Or Part Noncash Acquisition Equity Assumed NoncashOrPartNoncashAcquisitionEquityAssumed	122204000	usd
	carm	Noncash Or Part Noncash Acquisition Equity Assumed NoncashOrPartNoncashAcquisitionEquityAssumed	0	usd
	us-gaap	Notes Reduction NotesReduction	42447000	usd
	us-gaap	Notes Reduction NotesReduction	0	usd
	carm	Noncash Or Part Noncash Reverse Recapitalization Costs In Accrued Expenses NoncashOrPartNoncashReverseRecapitalizationCostsInAccruedExpenses	611000	usd
	carm	Noncash Or Part Noncash Reverse Recapitalization Costs In Accrued Expenses NoncashOrPartNoncashReverseRecapitalizationCostsInAccruedExpenses	0	usd
	carm	Noncash Or Part Noncash Unrealized Gain Loss On Marketable Securities NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities	306000	usd
	carm	Noncash Or Part Noncash Unrealized Gain Loss On Marketable Securities NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities	-197000	usd
	carm	Non Cash Deferred Financing Costs Accounts Payable NonCashDeferredFinancingCostsAccountsPayable	86000	usd
	carm	Non Cash Deferred Financing Costs Accounts Payable NonCashDeferredFinancingCostsAccountsPayable	0	usd
	carm	Non Cash Deferred Financing Costs Accrued Expenses NonCashDeferredFinancingCostsAccruedExpenses	60000	usd
	carm	Non Cash Deferred Financing Costs Accrued Expenses NonCashDeferredFinancingCostsAccruedExpenses	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	908000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6437000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	268000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	0	usd
	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	3820000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	993000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-202700000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	117100000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited interim consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant areas that require management’s estimates include the fair value of the Company’s common stock and the derivative liability prior to the Merger, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and development expenses.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of credit risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</span></div>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6655749	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16720159	shares
CY2023Q2	carm	Number Of Board Members NumberOfBoardMembers	7	seat
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	37873000	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Marketable Securities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities	44588000	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets	1316000	usd
CY2023Q1	carm	Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash	30000	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities	3499000	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	80308000	usd
CY2023Q1	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	8264000	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	72044000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	2875000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1898000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	593000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	15000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	88000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	4000	usd
	carm	Finance Lease Cost FinanceLeaseCost	681000	usd
	carm	Finance Lease Cost FinanceLeaseCost	19000	usd
	us-gaap	Lease Cost LeaseCost	3556000	usd
	us-gaap	Lease Cost LeaseCost	1917000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y2M12D
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y2M12D
CY2023Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M12D
CY2022Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M18D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.096
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.093
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	35000000	usd
CY2023Q1	carm	Stock Issued During Period Shares Conversion Of Convertible Preferred Stock And Non Controlling Interests StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests	18872711	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	10374272	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.090
CY2022Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.090
	us-gaap	Operating Lease Payments OperatingLeasePayments	2584000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	2367000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	88000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	4000	usd
	carm	Financing Cash Used In Finance Leases FinancingCashUsedInFinanceLeases	213000	usd
	carm	Financing Cash Used In Finance Leases FinancingCashUsedInFinanceLeases	17000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2344000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	1001000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	403000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	600000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	219000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	338000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	226000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	233000	usd
CY2023Q2	carm	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	424000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3849000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	1939000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	443000	usd
CY2023Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	118000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	3406000	usd
CY2023Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	1821000	usd
CY2023Q2	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	200000	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3730608	shares
CY2023Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	8.21
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	30600000	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	5059338	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3356937	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.01
	carm	Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Merger In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross	765223	shares
	carm	Share Based Compensation Arrangements By Share Based Payment Award Options Assumed In Merger Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice	27.94
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	14910	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.07
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2747152	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.17
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	87275	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.46
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	111378	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	23.52
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6655749	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.26
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	29956000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2961132	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.98
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M12D
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	18575000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	6655749	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	6.26
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y6M
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	29956000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.43
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.75
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	330000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	58000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	595000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	147000	usd
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	12700000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y9M18D
	carm	Tax Revenue Related To Collaboration And License Agreement With Related Party TaxRevenueRelatedToCollaborationAndLicenseAgreementWithRelatedParty	45000000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3600000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2700000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6800000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3500000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3600000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2700000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6800000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3500000	usd
CY2023Q2	carm	Revenue Remaining Performance Obligation Research And Development Amount RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount	57816000	usd
CY2023Q2	carm	Revenue Remaining Performance Obligation Option Rights Amount RevenueRemainingPerformanceObligationOptionRightsAmount	45000000	usd
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	102816000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	47459000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
	carm	Contract With Customer Liability Deferral Of Revenue ContractWithCustomerLiabilityDeferralOfRevenue	5760000	usd
	carm	Contract With Customer Liability Deferral Of Revenue ContractWithCustomerLiabilityDeferralOfRevenue	48972000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-6803000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-3525000	usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	46416000	usd
CY2022Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	45447000	usd

Files In Submission

Name	View Source	Status
0001485003-23-000116-index-headers.html	Edgar Link	pending
0001485003-23-000116-index.html	Edgar Link	pending
0001485003-23-000116.txt	Edgar Link	pending
0001485003-23-000116-xbrl.zip	Edgar Link	pending
carm-20230630.htm	Edgar Link	pending
carm-20230630.xsd	Edgar Link	pending
carm-20230630xexx311.htm	Edgar Link	pending
carm-20230630xexx312.htm	Edgar Link	pending
carm-20230630xexx321.htm	Edgar Link	pending
carm-20230630xexx322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
carm-20230630_def.xml	Edgar Link	unprocessable
carm-20230630_lab.xml	Edgar Link	unprocessable
carm-20230630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
carm-20230630_htm.xml	Edgar Link	completed
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
carm-20230630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CARM
Carisma Therapeutics Inc Stock $carm

2023 Q3 Form 10-Q Financial Statement

#000148500323000116 Filed on August 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CARM Carisma Therapeutics Inc Stock $carm

2023 Q3 Form 10-Q Financial Statement

#000148500323000116 Filed on August 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CARM
Carisma Therapeutics Inc Stock $carm